Significantly, the upregulated MP genes were enriched, while the downregulated MP genes were depleted in the transcriptomes of residual tumors (Fig. 2e, f; Supplementary Data 4a, b), suggesting that the mTOR-regulated persister state may be responsible for the minimal residual disease phenotype following clinical cancer chemotherapy. Here, MTOR is linked to cancer.